EXAI Exscientia Plc

FDA Catalyst Company
9.46
+0.62  (+7%)
Previous Close 8.84
Open 8.89
52 Week Low 6.56
52 Week High 30.38
Market Cap $1,143,574,457
Shares 120,886,527
Float 120,886,527
Enterprise Value $257,598,854
Volume 50,911
Av. Daily Volume 158,107
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/11/2022
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/26/2021
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/26/2021
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/26/2021

Latest News

  1. Exscientia (NASDAQ:EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T.

    A live webcast of the fireside chat will be available on the Company's website, under the "Investors & Media" section at www.investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

    About Exscientia
    Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision…

    View Full Article
  2. Exscientia plc (NASDAQ:EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new research in three poster presentations.

    "We are looking forward to meeting with some of the world's leading cancer clinicians and researchers at this year's AACR meeting, as we continue to build our human tissue precision medicine platform and expand the areas we are exploring to include additional indications such as breast and ovarian cancers," said Nikolaus Krall, Exscientia's VP of Precision Medicine. "In addition, we will share data highlighting our translational…

    View Full Article
  3. Exscientia plc (NASDAQ:EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia's portfolio of investigational medicines. Exscientia's drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit.

    "We want to be as innovative in the clinic as we have been in drug discovery. Mike is a proven innovator and strategic leader at the vanguard…

    View Full Article
  4. Exscientia plc (NASDAQ:EXAI)

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005753/en/

    (Graphic: Business Wire)

    (Graphic: Business Wire)

    Recent advancements in the Company's pipeline, collaborations and operations as well as financial results for the fourth quarter and full year 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, March 24 at 12:30 p.m. GMT / 8:30 a.m. ET to provide an overview of the company's end-to-end technology platform and progress towards automating drug discovery and development.

    Recent Highlights

    Progressed pipeline led by significant collaborations, expansion, and programme advancement

    - Year-over-year pipeline progress with 11 new…

    View Full Article
  5. Company to host conference call and webcast on March 24, 2022 at 12:30 p.m. GMT / 8:30 a.m. ET

    Exscientia (NASDAQ:EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. ET on Thursday, March 24, 2022, to provide an overview of the company's unique end-to-end technology platform and Exscientia's work to fully automate drug discovery and development.

    A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed…

    View Full Article
View All Exscientia Plc News